Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma (RCC). A retrospective study comparing interferon-alpha-2a/ vinblastine versus interferon-alpha-2a/interleukin-2/5-fluorouracil;Bedeutung der immunochemotherapie für das überleben von patienten mit metastasiertem nierenzellkarzinom. Eine retrospektive studie der therapie-gruppen interferon-α2a/vinblastin vs. interferon-α2a/ interleukin-2/5-fluorouracil

Urologe - Ausgabe A

Volumn 43, Issue 9, 2004, Pages 1111-1119

  May, M ^a,b   Helke, C ^a   Bock, M ^a   Hoschke, B ^a  

^a CARL THIEM KLINIKUM   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Metastasis; Overall survival; Remission rates; Renal cell carcinoma; Toxicity profile

Indexed keywords

ALPHA2A INTERFERON; FLUOROURACIL; INTERLEUKIN 2; LIVER ENZYME; VINBLASTINE;

ADULT; AGED; ALOPECIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CENTRAL NERVOUS SYSTEM DISEASE; DRUG SAFETY; ERYTHEMA; EXHAUSTION; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HEART INFARCTION; HUMAN; KIDNEY CARCINOMA; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; NEUTROPENIA; PATIENT COMPLIANCE; POLYNEUROPATHY; PROGNOSIS; RETROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GERMANY; HUMANS; IMMUNOTHERAPY; INTERFERON ALFA-2A; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINBLASTINE;

EID: 4744353087     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-004-0626-2     Document Type: Article

References (22)

1. Vasselli JR, Shih JH, Iyengar SR, Maranchie J, Riss J, Worrell R, Linehan WM (2003) Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proc Natl Acad Sci USA 100: 6958-6963
2. Atzpodien J, Kuchler T, Wandert T, Reitz M (2003) Rapid deterioration in quality of life during interleukin-2-and alpha-interferon-based home therapy of renal cell carcinoma is associated with a good outcome. Br J Cancer 89: 50-54
3. Brinkmann OA, Roigas J, Hertle L (2002) Systemic immunotherapy of metastatic renal cell carcinoma and long-term outcome. Urologe A 41: 231-238
4. Oberneder R, Kriegmair M, Staehler M, Hofstetter A (1997) Immunotherapy of metastatic renal cell carcinoma. Is clinical use justified in view of outcome, side effects and costs? Urologe A 36: 130-137
5. Volkmer BG, Gschwend JE (2002) Value of metastases surgery in metastatic renal cell carcinoma. Urologe A 41: 225-230
6. Isaacs A, Lindemann J (1957) Virus interference, I: the interferon. Proc R Soc Lond 147: 258-267
7. Quesada JR, Swanson DA, Trindade A, Gutterman JU (1983) Renal cell carcinoma: antitumor effects of leukocyte interferon. Cancer Res 43: 940-947
8. Jacqmin D, Bergerat JP, Dufour P et al. (1987) Medical treatment of metastatic cancer of the kidney with a combination of vinblastine and recombinant interferon alpha IIa. Result of a phase I-II trial. J Urol (Paris) 93: 463-436
9. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20: 289-296
10. Pyrhonen S, Salminen E, Ruutu M, Lehtonen T, Nurmi M, Kellokumpu-Lehtinen PL (1999) Prospective randomized trial of interferon alpha-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17: 2859-2867
11. Fossa SD, Martinelli G, Otto U et al. (1992) Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study. Ann Oncol 3: 301-305
12. Huland E, Heinzer H, Timm S, Alamian M, Huland H (2002) Immunotherapy of metastatic renal cell carcinoma in Germany. An assessment of the current status. Urologe A 41: 282-287
13. Negrier S, Escudier B, Lasset C et al. (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 338: 1272-1278
14. Atzpodien J, Kirchner H, Hanninen EL, Deckert M, Fenner M, Poliwoda H (1993) Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer A 29 (Suppl 5): 6-8
15. Atzpodien J, Kirchner H, Illiger HJ et al. (2001) IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 85: 1130-1136
16. Kirchner H (1998) Risks and long-term outcome in metastatic renal cell carcinoma patients receiving sc interleukin-2, sc interferon-alfa2a and iv 5-fluorouracil. Abstract presented at ASCO 1998, Abstract 1195
17. Atzpodien J, Kirchner H (2004) Interleukin-2- and Interferon Alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: A prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 22: 1188-1194
18. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17: 2530-2540
19. Lopez Hanninen E, Kirchner H, Atzpodien J (1996) Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol 155: 19-25
20. Atzpodien J, Royston P, Wandert T, Reitz, German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group (DGCIN) (2003) Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 88: 348-353
21. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R, European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358: 966-970
22. Flanigan RC, Salmon SE (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345: 1655-1659